MARKET

ALLK

ALLK

Allakos
NASDAQ
1.110
+0.080
+7.77%
After Hours: 1.140 +0.03 +2.70% 19:59 06/21 EDT
OPEN
1.060
PREV CLOSE
1.030
HIGH
1.140
LOW
1.050
VOLUME
813.84K
TURNOVER
0
52 WEEK HIGH
5.64
52 WEEK LOW
0.9799
MARKET CAP
98.28M
P/E (TTM)
-0.4528
1D
5D
1M
3M
1Y
5Y
Cantor Fitzgerald Reiterates Neutral on Allakos
Benzinga · 2d ago
Weekly Report: what happened at ALLK last week (0610-0614)?
Weekly Report · 6d ago
Weekly Report: what happened at ALLK last week (0603-0607)?
Weekly Report · 06/10 09:28
Weekly Report: what happened at ALLK last week (0527-0531)?
Weekly Report · 06/03 09:29
Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Clene (CLNN)
TipRanks · 05/28 14:20
Analysts Offer Insights on Healthcare Companies: Allakos (ALLK), Calliditas Therapeutics (CALT) and Clene (CLNN)
TipRanks · 05/28 14:10
Analysts Offer Insights on Healthcare Companies: Clene (CLNN) and Allakos (ALLK)
TipRanks · 05/28 14:01
ALLAKOS INC - TOP-LINE PHASE 1 CSU RESULTS EXPECTED AT YEAR END 2024
Reuters · 05/28 11:02
More
About ALLK
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.

Webull offers Allakos Inc stock information, including NASDAQ: ALLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLK stock methods without spending real money on the virtual paper trading platform.